Having trouble accessing articles? Reset your cache.

July 26 preclinical Quick Takes: Ribon's new mechanism for PARP inhibitors, a microbiome-ALS link and more

Ribon co-founder reports new mechanism for PARP inhibitors
An University of Texas Southwestern team led by Ribon Therapeutics Inc. (Lexington, Mass.) co-founder W. Lee Kraus reported that PARP inhibitors block ribosome production, and therefore tumor cell growth, by reducing nucleolar localization of

Read the full 429 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers